🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. DS-8201a

    AstraZeneca AB

    HER2 Expressing Tumors

    phase 2 small molecule active

    1 trial

  2. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  3. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  4. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. DURVALUMAB , Ifinatamab Deruxtecan, MK-6070

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  6. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  7. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  8. DYNE-101, The placebo is commercially available 0.9% (w/v) saline solution intended for IV

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial

  9. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  10. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  11. Dacogen 50 mg powder for concentrate for solution for infusion., Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    Fondazione Telethon ETS

    Acute Myeloid Leukemia secondary to myeloproliferative neoplasms

    phase 2 small molecule active

    1 trial

  12. Dantrolene sodium semiheptahydrate, SODIUM CHLORIDE, VISTABEL 4 Allergan-Einheiten/0,1 ml Pulver zur Herstellung einer Injektionslösung, FTP-002/FTP-501 combination

    Lacuna Pharma Pty Ltd

    glabellar lines.

    phase 2 small molecule active

    1 trial

  13. Dapagliflozin 10mg Tab

    The University of Hong Kong

    Lupus Nephritis

    phase 2 small molecule active

    1 trial

  14. Daratumumab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  15. Daratumumab, Ixazomib, Dexamethasone

    Takeda

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. Daridorexant matching placebo, QUVIVIQ 50 mg film-coated tablets, QUVIVIQ 25 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  17. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  18. Dasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία, Maltodextrine powder, SPRYCEL 20 mg film-coated tablets

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  19. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  20. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. Daxdilimab

    Amgen

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  22. Decitabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  23. Decitabine

    CATALYST PHARMACEUTICALS, INC.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  24. Decitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources